How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cutaneous Squamous Cell Carcinoma (cSCC) Market
- By Treatment Type: Surgical Excision, Mohs Micrographic Surgery, Radiation Therapy, Topical Chemotherapy, Systemic Therapy
- By Stage of Disease: Localized cSCC, Locally Advanced cSCC, Metastatic cSCC
- By Therapeutic Class: Immune Checkpoint Inhibitors, EGFR Inhibitors, Chemotherapeutic Agents, Targeted Therapy
- By Patient Demographics: Immunocompetent Patients, Immunosuppressed Patients, Elderly Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Surgical Excision leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.162 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.170 →
Full report · locked preview
Everything inside the Cutaneous Squamous Cell Carcinoma (cSCC) Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Stage of Disease 3
Therapeutic Class 4
Patient Demographics 3
Companies profiled
Regeneron Pharmaceuticals
Amgen Inc.
Sun Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Merck & Co. Inc.
Novartis AG
Eisai Co. Ltd.
Sanofi
Astellas Pharma Inc.
Pfizer Inc.
Eli Lilly and Company
Bayer AG
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Regeneron Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Amgen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sun Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Eisai Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Astellas Pharma Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Ipsen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Pierre Fabre
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Lilly Oncology
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,126M by 2033 · 9.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Surgical Excision48.8
- Mohs Micrographic Surgery11.2
- Radiation Therapy14.5
- Topical Chemotherapy14.4
- Systemic Therapy11.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$181.9M → $374.3M · 9.4%
Europe$126.8M → $242.6M · 8.5%
Asia Pacific$115.7M → $212.3M · 7.9%
Latin America$71.7M → $130.1M · 7.7%
Middle East and Africa$55.1M → $113.3M · 9.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.292026
9.322027
9.332028
9.322029
9.332030
9.352031
9.362032
9.372033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Regeneron Pharmaceuticals27.0
- Amgen Inc.13.1
- Sun Pharmaceutical Industries Ltd.11.4
- Bristol-Myers Squibb6.7
- Merck & Co. Inc.6.7
- Novartis AG7.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type31.1%
Stage of Disease31.2%
Therapeutic Class23.9%
Patient Demographics13.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe22.6
- Asia Pacific19.8
- Latin America12.1
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | 75 | 95 | 88 | 82 | 97 | 90 | 88 |
| Amgen Inc. | 82 | 75 | 73 | 87 | 91 | 88 | 83 |
| Sun Pharmaceutical Industries Ltd. | 87 | 82 | 75 | 64 | 88 | 81 | 80 |
| Bristol-Myers Squibb | 57 | 59 | 80 | 69 | 62 | 81 | 68 |
| Merck & Co. Inc. | 71 | 55 | 74 | 65 | 60 | 53 | 63 |
| Novartis AG | 54 | 47 | 60 | 59 | 53 | 46 | 53 |
| Eisai Co. Ltd. | 50 | 43 | 58 | 60 | 51 | 53 | 53 |
| Sanofi | 53 | 48 | 39 | 58 | 51 | 44 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Regeneron Pharmaceuticals
- Amgen Inc.
- Sun Pharmaceutical Industries Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Amgen Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Sun Pharmaceutical Industries Ltd. | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Bristol-Myers Squibb | − | − | ✓ | − | ◐ | ✓ |
| Merck & Co. Inc. | ◐ | ◐ | ◐ | − | − | ◐ |
| Novartis AG | − | ◐ | ◐ | − | ◐ | − |
| Eisai Co. Ltd. | − | − | ◐ | ◐ | − | − |
| Sanofi | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Regeneron Pharmaceuticals88
2Amgen Inc.83
3Sun Pharmaceutical Industries Ltd.80
4Bristol-Myers Squibb68
5Merck & Co. Inc.63
6Novartis AG53
7Eisai Co. Ltd.53
8Sanofi49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Regeneron PharmaceuticalsAmgen Inc.Sun Pharmaceutical Industries Ltd.
Challenger1
Strong scale, closing on the leaders.
Bristol-Myers Squibb
Contender1
Focused players with pockets of strength.
Merck & Co. Inc.
Niche3
Specialists in a single segment or region.
Novartis AGEisai Co. Ltd.Sanofi
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Cutaneous Squamous Cell Carcinoma (cSCC) Market — a $541M beachhead inside a $8.91B market.
Beachhead (SOM)$541Mobtainable near-term
Serviceable (SAM)$3.72Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Surgical Excision
Best fit — highest urgency & budget in Treatment Type.
Economic buyer79 fit
Mohs Micrographic Surgery
Strong fit — clear ROI and a fast path to value.
End user64 fit
Radiation Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Stage of Disease & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cutaneous Squamous Cell Carcinoma (cSCC) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified24%
Evaluation12%
Closed-won7%
$10.8KCAC
$57KLTV
5.3:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cutaneous Squamous Cell Carcinoma (cSCC) Market is a resilient opportunity — $8.67B by 2033, compounding at 5.8%.
TAM · 2025$5.53Btoday
TAM · 2033$8.67Bforecast
CAGR5.8%2027–2033
Cumulative$63.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.67BTotal addressable market
SAM$3.33BServiceable available market
SOM$718MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.8% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.67BLarge & growingTAM by 2033 at 5.8% CAGR
$3.33BServiceable nowreachable with today’s model
$718MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.76BBear3.8% CAGR
$8.67BBase5.8% CAGR
$11.1BBull7.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Stage of Disease optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cutaneous Squamous Cell Carcinoma (cSCC) Market — a $3.56B market by 2033. Plan: grow share from 7.5% to 14.6%.
Market size · 2033$3.56Btotal addressable
Market CAGR11.2%2027–2033
Target share14.6%from 7.5% today
Revenue ambition$520Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 14.6% | Behind |
| Revenue | $248M | $520M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.0% | 44.4% | On track |
| Customer retention | 86.6% | 92.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Stage of Disease capability
A defensible second engine — invest in Stage of Disease to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Stage of Disease
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $54M capacity & capability investment
- Greenlight bolt-on M&A in Stage of Disease
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cutaneous Squamous Cell Carcinoma (cSCC) Market conversation — a $2.58B market you can size, segment and defend in minutes.
Market size · 2033$2.58Btotal opportunity
Growth3.3%CAGR to 2033
Addressable buyers1,375+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 2 mopayback period
$47K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Regeneron PharmaceuticalsAmgen Inc.Sun Pharmaceutical Industries Ltd.Bristol-Myers SquibbMerck & Co. Inc.Novartis AGEisai Co. Ltd.Sanofi+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cutaneous Squamous Cell Carcinoma (cSCC) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cutaneous Squamous Cell Carcinoma (cSCC) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cutaneous T-cell Lymphoma (CTLC) Market
Market size, share, segmentation and regional forecast.
$703M market · 2025 base year
View reportCutaneous T-Cell Lymphoma(CTCL) Market
Market size, share, segmentation and regional forecast.
$796M market · 2025 base year
View reportCutlery and Bath Fittings Electroplating Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCutlery Steel Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportCutoff Valve Spool Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCutter Bar Market
Market size, share, segmentation and regional forecast.
$535M market · 2025 base year
View reportCutter Blades Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCutter Clearance Gauge Market
Market size, share, segmentation and regional forecast.
$789M market · 2025 base year
View reportCutter Grinding Machines Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportCutter Head Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCutter Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCutter Mill Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.